Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sarepta Therapeutics Inc Sees FY 2012 Revenue Guidance At Low End Of Prior Range; Reaffirms FY 2012 Earnings Guidance


Wednesday, 7 Nov 2012 04:05pm EST 

Sarepta Therapeutics Inc announced that for fiscal 2012, it expects revenue will be at the lower end of the previously issued guidance of $37-$43 million. Additionally, operating loss is expected to be within the previous disclosed range of $25-$30 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $43 million and EBIT of $(25) million for fiscal 2012. 

Company Quote

22.94
0.64 +2.87%
17 Sep 2014